Numab Therapeutics AG announced that the first subject has been dosed in the Phase 1 clinical study of NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis.
Numab Therapeutics AG announced that the first subject has been dosed in the Phase 1 clinical study of NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis.